Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)
Saved in:
| Title: | Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415) |
|---|---|
| Authors: | Lorenzen, Sylvie1 (AUTHOR) sylvie.lorenzen@mri.tum.de, Schwarz, Alix1 (AUTHOR), Pauligk, Claudia2 (AUTHOR), Goekkurt, Eray3 (AUTHOR), Stocker, Gertraud4 (AUTHOR), Knorrenschild, Jorge Riera5 (AUTHOR), Illerhaus, Gerald6 (AUTHOR), Dechow, Tobias7 (AUTHOR), Moehler, Markus8 (AUTHOR), Moulin, Jean-Charles9 (AUTHOR), Pink, Daniel10 (AUTHOR), Stahl, Michael11 (AUTHOR), Schaaf, Marina2 (AUTHOR), Goetze, Thorsten Oliver2,12 (AUTHOR), Al-Batran, Salah-Eddin2,12 (AUTHOR) |
| Source: | BMC Cancer. 6/19/2023, Vol. 23 Issue 1, p1-8. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
